Search
-
ViiV Healthcare receives EU Marketing Authorisation for Dovato (dolutegravir/lamivudine), a new once-daily, single-pill, two-drug regimen for the treatment of HIV-1 infection
Media
Dovato achieved non-inferior efficacy compared to a dolutegravir-based, three-drug regimen through 48 weeks.
https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-receives-eu-marketing-authorisation-for-dovato-dolutegravirlamivudine-a-new-once-daily-single-pill-two-drug-regimen-for-the-treatment-of-hiv-1-infection/
First published: 03 July 2019
-
ViiV Healthcare and the Medicines Patent Pool sign new voluntary licensing agreement to expand access to innovative long-acting HIV prevention medicine
Media
Selected generic manufacturers will have the opportunity to develop, manufacture and supply generic versions of cabotegravir LA for PrEP
https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-and-the-medicines-patent-pool-sign-new-voluntary-licensing-agreement/
First published: 28 July 2022
-
Juluca (dolutegravir/rilpivirine), the first single pill, 2-drug regimen, for the maintenance treatment of HIV, granted marketing approval by Japan Ministry of Health, Labour and Welfare
Media
The Ministry of Health, Labour and Welfare has approved Juluca Combination Tablets for the maintenance treatment of (HIV-1) infection.
https://www.gsk.com/en-gb/media/press-releases/juluca-dolutegravirrilpivirine-the-first-single-pill-2-drug-regimen-for-the-maintenance-treatment-of-hiv-granted-marketing-approval-by-japan-ministry-of-health-labour-and-welfare/
First published: 26 November 2018
-
ViiV Healthcare receives EU marketing authorisation for Juluca (dolutegravir/rilpivirine), the first 2-drug regimen, once-daily, single-pill for the treatment of HIV
Media
Juluca maintains viral suppression with two drugs in the smallest single pill regimen
https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-receives-eu-marketing-authorisation-for-juluca-dolutegravirrilpivirine-the-first-2-drug-regimen-once-daily-single-pill-for-the-treatment-of-hiv/
First published: 21 May 2018
-
GSK presents scientific advances to improve patient outcomes at the American Association for the Study of Liver Diseases’ The Liver Meeting® 2023
Media
New data from the B-Together phase IIb trial contribute to the development of a functional cure for people living with CHB.
https://www.gsk.com/en-gb/media/press-releases/gsk-presents-scientific-advances-to-improve-patient-outcomes-at-the-american-association-for-the-study-of-liver-diseases-the-liver-meeting-2023/
First published: 11 October 2023
-
ARIA study shows superior efficacy of Triumeq® for treatment-naïve women living with HIV
Media
ViiV Healthcare today presented 48-week data from the phase IIIb, open-label, international, multi-centre ARIA study
https://www.gsk.com/en-gb/media/press-releases/aria-study-shows-superior-efficacy-of-triumeq-for-treatment-naïve-women-living-with-hiv/
First published: 18 July 2016
-
EACS 2019: ViiV Healthcare to present 17 abstracts from its portfolio addressing the diverse needs of people living with HIV
Media
Data presentations expand understanding of ViiV Healthcare’s pipeline for heavily treatment-experienced populations.
https://www.gsk.com/en-gb/media/press-releases/eacs-2019-viiv-healthcare-to-present-17-abstracts-from-its-portfolio-addressing-the-diverse-needs-of-people-living-with-hiv/
First published: 06 November 2019
-
ViiV Healthcare announces US FDA approval of Cabenuva (cabotegravir, rilpivirine) for use every two months, expanding the label of the first and only complete long-acting HIV treatment
Media
Cabenuva is now approved for administration as few as six times a year for virologically suppressed adults living with HIV.
https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-us-fda-approval-of-cabenuva-cabotegravir-rilpivirine-for-use-every-two-months-expanding-the-label-of-the-first-and-only-complete-long-acting-hiv-treatment/
First published: 01 February 2022
-
ViiV Healthcare presents three-year switch data for Dovato (dolutegravir/lamivudine) confirming long-term, non-inferior efficacy with no virologic failure versus continuation of TAF-based regimens of at least three drugs
Media
The Phase 3 TANGO study is the 3rd trial to provide long-term evidence for Dovato reinforcing its use as a viable switch for people with HIV
https://www.gsk.com/en-gb/media/press-releases/viiv-presents-three-year-switch-data-for-dovato/
First published: 29 September 2021
-
ViiV Healthcare submits regulatory applications for the first HIV maintenance regimen comprising only two medicines
Media
ViiV Healthcare submits regulatory applications for the first HIV maintenance regimen comprising only two medicines
https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-submits-regulatory-applications-for-the-first-hiv-maintenance-regimen-comprising-only-two-medicines/
First published: 01 June 2017